T1	Condition 180 209	familial hypercholesterolemia
T2	Condition-Name 180 209	familial hypercholesterolemia
E1	Condition:T1 Name:T2
T3	Condition 66 90	cardiovascular morbidity
T4	Condition-Name 66 90	cardiovascular morbidity
E3	Condition:T3 Name:T4
T5	Condition 139 161	cardiovascular disease
T6	Condition-Name 139 161	cardiovascular disease
E5	Condition:T5 Name:T6
T7	Procedure 296 310	statin therapy
T8	Procedure-Name 296 310	statin therapy
E7	Procedure:T7 Name:T8 Temporality:E14
T9	Life-Stage-And-Gender 25 31	Adults
A1	Life-Stage-And-Gender-Type T9 adult
T10	Procedure 379 388	treatment
T11	Procedure-Name 379 388	treatment
E10	Procedure:T10 Name:T11 Temporality:E21
T12	Eq-Operator 32 33	≥
A2	Eq-Operator-Value T12 GTEQ
T13	Eq-Operator 221 236	within the past
A3	Eq-Operator-Value T13 LTEQ
T14	Eq-Operator 327 335	the past
A4	Eq-Operator-Value T14 GTEQ
T15	Eq-Temporal-Unit 37 42	years
A5	Eq-Temporal-Unit-Value T15 year
T16	Eq-Temporal-Unit 239 245	months
A6	Eq-Temporal-Unit-Value T16 month
T17	Eq-Temporal-Unit 338 344	months
A7	Eq-Temporal-Unit-Value T17 month
T18	Age 43 46	old
E11	Age:T18 
T19	Eq-Value 34 36	18
T20	Eq-Value 237 238	6
T21	Eq-Value 336 337	3
T22	Eq-Comparison 32 42	≥ 18 years
E12	Eq-Comparison:T22 Operator:T12 Temporal-Unit:T15 Value:T19
T23	Eq-Comparison 221 245	within the past 6 months
E13	Eq-Comparison:T23 Operator:T13 Temporal-Unit:T16 Value:T20
T24	Eq-Comparison 327 344	the past 3 months
E14	Eq-Comparison:T24 Operator:T14 Temporal-Unit:T17 Value:T21
R1	Equivalent-To Arg1:E11 Arg2:E12	
T25	Risk 52 61	High risk
E2	Risk:T25 Risk-For:E3 Risk-For2:E4
T26	Death 95 104	mortality
E4	Death:T26 
T27	And 91 94	and
E6	And:T27 Arg:E3 Arg2:E4
T28	Modifier 130 138	clinical
E8	Modifier:T28 Modifies:T6
T29	Or 162 168	and/or
E9	Or:T29 Arg:E5 Arg2:T2
T30	Observation 215 220	LDL-C
E15	Observation:T30 Name:T31 Temporality:E13 Minimum-Count:E16
T31	Observation-Name 215 220	LDL-C
A8	Observation-Type-Value T31 lab
T32	Eq-Comparison 246 269	above recommended level
E16	Eq-Comparison:T32 Operator:T33 Value:T34
T33	Eq-Operator 246 251	above
A9	Eq-Operator-Value T33 GT
T34	Eq-Value 252 269	recommended level
T35	Drug 313 322	ezetimibe
E17	Drug:T35 Name:T36
T36	Drug-Name 313 322	ezetimibe
R2	Using Arg1:E7 Arg2:E17	
T37	Modifier 278 295	maximal tolerated
E18	Modifier:T37 
R3	Abbrev-Of Arg1:E18 Arg2:E7	
T38	And 270 277	despite
E19	And:T38 Arg:E15 Arg2:E7
T39	Drug 394 409	PCSK9 inhibitor
E20	Drug:T39 Name:T40
T40	Drug-Name 394 409	PCSK9 inhibitor
R4	Using Arg1:E10 Arg2:E20	
T41	Eq-Comparison 371 378	Current
E21	Eq-Comparison:T41 
T42	Eq-Temporal-Period 371 378	Current
A10	Eq-Temporal-Period-Value T42 present
T43	Study 456 461	study
E22	Study:T43 Temporality:E23
T44	Eq-Comparison 415 422	Current
E23	Eq-Comparison:T44 Temporal-Period:T45
T45	Eq-Temporal-Period 415 422	Current
A11	Eq-Temporal-Period-Value T45 present
